Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of $0.71, $0.20 better than the analyst estimate of $0.51. Revenue for the quarter came in at $4.04 billion versus the consensus estimate of $3.8 billion.

Bristol-Myers Squibb sees FY2015 adjusted EPS from $1.55-$1.70 to $1.60-$1.70, versus the consensus of $1.72.

“We have started the year off with strong sales among new and inline brands, including Yervoy,Eliquis, our hepatitis C franchise and Opdivo, and brought important new medicines to patients with cancer and HIV,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “We continued to advance our pipeline with key regulatory and clinical progress across our portfolio and invested in several important business development opportunities that will help strengthen our future portfolio.”

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.